The invention provides the components of
in vivo and
in vitro systems and methods which use them to study the effects of altered expression of a
gene activity, such as the human akt, bcl-2, eIF4E or
PTEN activities, on the descendants of stem cells that have been engineered to give rise to hematopoietic tumorigenic or
tumor cells, such as lymphomas, with a
high frequency. The present invention provides vectors, cells and mammals, and methods which in part depend on such products, useful for understanding tumorigenesis and its treatments, and in particular, for identifying and studying inhibitors and activators associated with tumor
cell growth and
growth inhibition,
cell death through apoptotic pathways, and changes in apoptotic pathway components that affect
drug sensitivity and resistance in tumorigenic cells. Methods for identifying
molecular targets for
drug screening, identifying interacting
gene activities, for identifying therapeutic treatments and for identifying candidates for new therapeutic treatments are provided.